Current Report Filing (8-k)
December 14 2021 - 04:18PM
Edgar (US Regulatory)
0001622879 false 0001622879 2021-12-09
2021-12-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
Date of Report (Date of earliest event reported):
December 9, 2021
Medicine Man Technologies, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Nevada |
|
001-36868 |
|
46-5289499 |
| (State or Other Jurisdiction of
Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification
No.) |
|
4880 Havana Street,
Suite 201
Denver,
Colorado
|
80239 |
| (Address of Principal Executive
Offices) |
(Zip
Code) |
| |
|
|
(303)
371-0387 |
| (Registrant’s Telephone Number, Including Area
Code) |
| |
|
|
Not Applicable |
| (Former Name or Former Address, if Changed Since
Last Report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of Each
Class |
|
Trading Symbol(s) |
|
Name of Each Exchange On Which
Registered |
|
Not applicable |
|
Not applicable |
|
Not
applicable |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security
Holders.
On December 9, 2021, Medicine Man Technologies, Inc. (the
“Company”) held its 2021 Annual Meeting of Stockholders (the
“Annual Meeting”). The matters voted upon and the results of the
vote are set forth below.
Proposal 1: Election of Directors.
The Company’s stockholders elected all nominees named in the proxy
statement for the Annual Meeting to the Company’s board of
directors, each to serve as a Class B director for a two-year term
expiring at the Company’s annual meeting of stockholders to be held
in 2023 and until his successor is elected and qualified, or until
his earlier death, resignation or removal, with the following
vote:
| |
|
For |
|
Against |
|
Abstain |
|
Broker non-votes |
| Justin Dye |
|
61,446,316 |
|
198,254 |
|
31,348 |
|
11,664,313 |
| Pratap Mukharji |
|
61,461,035 |
|
171,512 |
|
43,371 |
|
11,664,313 |
| Brian Ruden |
|
61,458,234 |
|
167,966 |
|
49,781 |
|
11,664,313 |
Proposal 2: Ratification of Appointment of Independent Public
Accountant.
The Company’s stockholders ratified the appointment of BF Borgers,
CPA P.C. as the Company’s independent public accountant for the
fiscal year ending December 31, 2021, with the following vote:
|
For |
|
Against |
|
Abstain |
|
Broker non-votes |
| 73,160,395 |
|
62,543 |
|
117,293 |
|
0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
MEDICINE MAN
TECHNOLOGIES, INC. |
| |
|
| |
By: |
/s/
Daniel R.
Pabon |
|
Date: December 14, 2021
|
|
Daniel R. Pabon
General Counsel |
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Apr 2022 to May 2022
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From May 2021 to May 2022
